Back

Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from Takeda

Sidley represented Axsome Therapeutics, Inc. (Nasdaq: AXSM), in its acquisition of exclusive global rights from Takeda Pharmaceutical Co. Ltd. to TAK-063 (balipodect), a novel and selective inhibitor for the treatment of schizophrenia and Tourette syndrome. Under the agreement, Takeda received an upfront payment and is eligible to receive royalties and payments related to development, regulatory, and commercial milestones. Axsome plans to begin Phase 3 trial-enabling activities for the schizophrenia indication in 2026.
LEGAL DESIRE NEWSLETTER

Where the legal industry reads first.

Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.

No spam. Unsubscribe anytime.

From Legal Desire

Is your firm the one being cited, or the one being skipped?

We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.

See the full deal record on DealDatabase
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
Lavanya Dhamija
Reports Deals, Law firm and In-house updates